Hub : Traits :

Qualifications: A levels/AS levels or equivalent

460 significantly associated models · 88 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	41130424	42542658	1	1	2.3e-07	3.0e-07	9.4e-04	58	FOXO6
2	1	43152610	45153116	10	4	3.1e-12	3.9e-13	8.2e-01	100	ARTN MED8 ST3GAL3
3	1	71163715	73435171	1	1	8.2e-08	1.8e-08	1.8e-06	28	NEGR1
4	2	43899918	45698128	1	1	3.0e-08	5.4e-10	5.0e-03	80	CAMKMT
5	2	100193898	101731705	2	1	6.0e-10	2.4e-10	1.0e+00	100	LONRF2
6	2	156594333	158165818	1	1	8.3e-09	5.1e-09	3.2e-03	74	GPD2
7	2	161297929	162790882	1	1	4.0e-08	5.3e-10	1.5e-03	74	TANK
8	3	48029118	51043528	29	7	3.9e-26	1.4e-23	1.0e+00	100	APEH IP6K2 MST1R RBM6 RNF123 UBA7
9	3	84767271	86367480	1	1	3.4e-09	2.7e-08	5.6e-03	75	CADM2
10	4	151637154	153275701	1	1	2.4e-07	8.6e-08	1.2e-04	48	FAM160A1
11	5	59353199	61156570	4	1	6.3e-09	5.9e-09	1.6e-01	94	ERCC8
12	7	1161158	2969983	1	1	6.1e-08	1.5e-08	1.0e-02	79	MAD1L1
13	7	23913624	25432157	1	1	9.6e-09	5.5e-09	1.0e+00	100	MPP6
14	7	74339397	75842792	3	1	2.2e-07	4.2e-07	2.1e-01	94	POM121C
15	8	142629143	144515639	2	2	1.7e-08	2.6e-09	4.7e-03	78	THEM6 TSNARE1
16	10	10349662	12076043	1	1	7.6e-08	1.1e-08	7.2e-03	78	CELF2
17	10	64195778	65606229	2	1	1.4e-08	8.9e-09	6.0e-02	89	NRBF2
18	10	103940629	104440050	1	1	1.4e-07	4.9e-09	9.9e-03	81	CUEDC2
19	11	94805896	96276010	4	1	2.9e-13	1.1e-12	3.8e-01	98	AP001877.1
20	12	122713991	124591385	11	1	1.4e-14	7.4e-15	7.7e-02	95	RP11-282O18.3
21	16	9598191	10524165	1	1	1.4e-08	1.3e-10	1.8e-03	76	GRIN2A
22	19	36003721	36487759	1	1	2.9e-07	3.3e-06	3.7e-01	96	LIN37
23	19	45569009	46073472	1	1	3.4e-10	2.1e-08	3.7e-01	98	CKM

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.21	1	0	0.0	0.00	1.0e+00	MPP6
Bipolar Disorder or Schizophrenia	2.14	4	2	4.4	-0.20	8.0e-01	MED8 MPP6 RP11-282O18.3 ST3GAL3
Depressed Affect (Nagel 2018)	4.11	8	4	8.9	-0.98	3.3e-06	APEH CELF2 MST1R RBM6 RNF123 TANK THEM6 UBA7
Intelligence (Savage-Jansen 2018)	13.65	23	15	33.3	0.97	2.1e-16	AP001877.1 APEH ARTN CAMKMT CKM CUEDC2 ERCC8 FAM160A1 FOXO6 LIN37 LONRF2 MED8 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK TSNARE1 UBA7
Neuroticism (Nagel 2018)	2.08	3	0	0.0	0.00	1.0e+00	CELF2 THEM6 TSNARE1
Schizophrenia (2018)	2.85	4	0	0.0	-0.42	5.8e-01	ERCC8 MED8 RP11-282O18.3 ST3GAL3
Worry (Nagel 2018)	1.89	3	0	0.0	0.00	1.0e+00	AP001877.1 CADM2 TSNARE1
Crohns Disease (2017)	5.13	5	5	11.1	0.96	2.4e-03	APEH MST1R RBM6 RNF123 UBA7
Irritable Bowel Disease (IBD)	6.34	5	5	11.1	0.96	2.4e-03	APEH MST1R RBM6 RNF123 UBA7
Ulcerative Colitis (UC)	4.96	5	5	11.1	0.97	1.4e-03	APEH MST1R RBM6 RNF123 UBA7
Major Depression (MDD)	3.33	1	1	2.2	0.00	1.0e+00	NEGR1
Reaction Time	2.11	1	0	0.0	0.00	1.0e+00	RNF123
Verbal and Numeric Reasoning (VNR)	11.11	15	11	24.4	0.97	5.9e-11	APEH ARTN CKM CUEDC2 FAM160A1 FOXO6 LONRF2 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK UBA7
Breast Cancer	1.83	2	0	0.0	0.00	1.0e+00	APEH UBA7
Prostate Cancer	2.24	1	0	0.0	0.00	1.0e+00	UBA7
Age at First Birth	8.93	6	5	11.1	1.00	2.1e-06	APEH LONRF2 MST1R RBM6 RNF123 UBA7
Body Mass Index (BMI) (2010)	3.50	1	1	2.2	0.00	1.0e+00	NEGR1
Coronary Artery Disease (CAD)	2.86	1	0	0.0	0.00	1.0e+00	RBM6
Crohns Disease (2012)	5.14	5	5	11.1	0.98	4.3e-04	APEH MST1R RBM6 RNF123 UBA7
HDL Cholesterol	1.98	2	0	0.0	0.00	1.0e+00	NRBF2 RBM6
Neuroticism (2016)	2.23	1	0	0.0	0.00	1.0e+00	TANK
Schizophrenia (2014)	2.39	3	1	2.2	0.00	1.0e+00	ERCC8 RP11-282O18.3 ST3GAL3
Triglycerides	1.54	1	1	2.2	0.00	1.0e+00	NRBF2
Ulcerative Colitis	4.79	5	4	8.9	0.98	3.1e-03	APEH MST1R RBM6 RNF123 UBA7
Blood Eosinophil Count	1.10	4	3	6.7	-0.85	6.8e-02	CKM RBM6 RP11-282O18.3 UBA7
Blood Platelet Count	4.44	6	4	8.9	0.12	8.2e-01	CKM FAM160A1 MPP6 NRBF2 RP11-282O18.3 ST3GAL3
Blood Red Count	1.45	13	5	11.1	-0.48	1.0e-01	AP001877.1 CAMKMT CKM ERCC8 IP6K2 MED8 MST1R NRBF2 POM121C RBM6 RNF123 ST3GAL3 UBA7
Blood White Count	3.43	11	8	17.8	-0.69	1.3e-02	APEH CKM FAM160A1 FOXO6 MED8 MPP6 MST1R NRBF2 RBM6 RNF123 UBA7
Heel T-Score	2.38	7	6	13.3	-0.90	2.3e-03	APEH MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
BMI	7.79	14	11	24.4	-0.86	4.0e-05	APEH CADM2 CAMKMT IP6K2 LIN37 LONRF2 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 THEM6 UBA7
Height	1.20	12	6	13.3	0.84	6.4e-04	AP001877.1 CAMKMT ERCC8 FAM160A1 MED8 MPP6 MST1R NRBF2 POM121C RNF123 RP11-282O18.3 ST3GAL3
Waist Hip Ratio (WHR)	1.32	2	1	2.2	0.00	1.0e+00	ERCC8 RP11-282O18.3
Systolic Blood Pressure	2.13	7	3	6.7	-0.64	1.2e-01	APEH MED8 MPP6 POM121C RNF123 TSNARE1 UBA7
Smoking Status	4.37	6	5	11.1	-0.98	5.4e-04	CADM2 CELF2 ERCC8 MED8 ST3GAL3 TANK
Allergy or Eczema	1.60	2	0	0.0	0.00	1.0e+00	NEGR1 RP11-282O18.3
Cardiovascular Disease	2.15	4	1	2.2	-0.27	7.3e-01	MED8 NEGR1 RNF123 THEM6
Hypothyroidism (self reported)	1.34	1	1	2.2	0.00	1.0e+00	TANK
Respiratory disease	1.84	1	0	0.0	0.00	1.0e+00	RBM6
Type 2 Diabetes (T2D) (2018)	3.31	4	2	4.4	-0.99	4.3e-04	MST1R RBM6 RNF123 UBA7
Lung FEV1/FVC ratio	1.36	2	2	4.4	0.00	1.0e+00	NEGR1 NRBF2
Lung FVC	1.67	8	2	4.4	0.48	2.3e-01	APEH FOXO6 GPD2 MST1R NRBF2 RBM6 RP11-282O18.3 UBA7
Neuroticism	2.12	3	0	0.0	0.00	1.0e+00	RNF123 TSNARE1 UBA7
Chronotype (morning person)	1.77	1	0	0.0	0.00	1.0e+00	CAMKMT
Hair Pigment	0.12	1	1	2.2	0.00	1.0e+00	RP11-282O18.3
Tanning	0.45	1	0	0.0	0.00	1.0e+00	CADM2
Hand grip strength (left)	1.63	3	0	0.0	0.00	1.0e+00	CADM2 CUEDC2 FAM160A1
Number of treatments/medications taken	5.32	7	4	8.9	-0.87	5.3e-03	APEH MST1R NEGR1 RBM6 RNF123 TANK UBA7
Average weekly spirits intake	2.86	1	0	0.0	0.00	1.0e+00	APEH
Frequency of depressed mood in last 2 weeks	1.90	1	0	0.0	0.00	1.0e+00	CELF2
Relative age of first facial hair	1.75	2	0	0.0	0.00	1.0e+00	MED8 NRBF2
Systolic blood pressure, automated reading	2.66	6	2	4.4	-0.75	8.6e-02	APEH MED8 MPP6 RNF123 TSNARE1 UBA7
Supplements: Zinc	1.92	1	0	0.0	0.00	1.0e+00	NRBF2
Medication: Co-codamol	3.52	4	0	0.0	-1.00	4.1e-06	MST1R RBM6 RNF123 UBA7
Impedance of leg (right)	2.29	9	5	11.1	0.47	1.7e-01	AP001877.1 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 UBA7
Leg fat-free mass (left)	3.36	11	8	17.8	-0.53	7.4e-02	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Trunk fat percentage	5.10	12	8	17.8	-0.89	3.9e-05	APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Hand grip strength (right)	1.88	3	0	0.0	0.00	1.0e+00	CADM2 CUEDC2 FAM160A1
Townsend deprivation index at recruitment	1.97	1	0	0.0	0.00	1.0e+00	CKM
Current tobacco smoking	3.24	1	0	0.0	0.00	1.0e+00	ST3GAL3
Maternal smoking around birth	4.27	3	0	0.0	0.00	1.0e+00	CKM MED8 RNF123
Fed-up feelings	5.24	7	4	8.9	-0.99	6.6e-06	APEH LONRF2 MST1R RBM6 RNF123 THEM6 UBA7
Relative age voice broke	2.07	2	0	0.0	0.00	1.0e+00	NRBF2 POM121C
Taking other prescription medications	5.07	4	4	8.9	-1.00	1.4e-05	MST1R RBM6 RNF123 UBA7
Age when periods started (menarche)	3.90	7	3	6.7	-0.74	5.6e-02	APEH MED8 MST1R NEGR1 NRBF2 RBM6 ST3GAL3
Heel bone mineral density (BMD) T-score, automated (left)	2.58	4	2	4.4	-0.99	7.1e-04	MST1R RBM6 RNF123 UBA7
Qualifications: CSEs or equivalent	4.41	6	0	0.0	-0.98	7.3e-04	FOXO6 MST1R RBM6 RNF123 ST3GAL3 UBA7
High blood pressure	1.96	4	0	0.0	-0.11	8.9e-01	MED8 NEGR1 NRBF2 TSNARE1
Hayfever, allergic rhinitis or eczema	1.82	3	0	0.0	0.00	1.0e+00	IP6K2 NEGR1 RP11-282O18.3
Sitting height	1.47	4	2	4.4	0.93	6.9e-02	CAMKMT MED8 RP11-282O18.3 ST3GAL3
Body mass index (BMI)	8.63	15	9	20.0	-0.89	4.2e-06	APEH CADM2 CAMKMT IP6K2 LIN37 LONRF2 MPP6 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 THEM6 UBA7
Impedance of leg (left)	2.37	10	5	11.1	0.38	2.6e-01	AP001877.1 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Leg predicted mass (left)	3.34	11	8	17.8	-0.53	7.6e-02	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Trunk fat mass	5.57	11	8	17.8	-0.88	1.6e-04	APEH CADM2 IP6K2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Waist circumference	5.78	10	8	17.8	-0.85	9.8e-04	APEH CADM2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Past tobacco smoking	3.01	3	1	2.2	0.00	1.0e+00	CADM2 CELF2 TANK
Alcohol usually taken with meals	5.75	7	1	2.2	1.00	6.1e-07	CADM2 ERCC8 GRIN2A MED8 NEGR1 NRBF2 TSNARE1
Nervous feelings	1.77	3	1	2.2	0.00	1.0e+00	AP001877.1 CADM2 TSNARE1
Forced vital capacity (FVC)	1.60	5	0	0.0	0.75	1.5e-01	APEH FAM160A1 FOXO6 MST1R UBA7
Heel bone mineral density (BMD) T-score, automated (right)	2.34	4	1	2.2	-0.99	9.3e-04	MST1R RBM6 RNF123 UBA7
Qualifications: None of the above	14.53	24	18	40.0	-0.98	1.3e-17	AP001877.1 APEH ARTN CAMKMT CELF2 CKM ERCC8 FAM160A1 GRIN2A LONRF2 MED8 MPP6 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK THEM6 TSNARE1 UBA7
Allergy	1.69	2	1	2.2	0.00	1.0e+00	NEGR1 RP11-282O18.3
Diabetes (self-reported)	3.84	3	2	4.4	-1.00	3.9e-03	RBM6 RNF123 UBA7
Fluid intelligence score	11.22	17	9	20.0	0.99	1.7e-14	APEH ARTN CAMKMT CELF2 CKM FAM160A1 FOXO6 LONRF2 MED8 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK UBA7
Illnesses of siblings	2.44	1	0	0.0	0.00	1.0e+00	ST3GAL3
Neuroticism score	2.28	3	0	0.0	0.00	1.0e+00	CELF2 RNF123 UBA7
Weight	5.69	11	8	17.8	-0.76	4.4e-03	APEH CADM2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 THEM6 UBA7
Impedance of arm (right)	4.49	9	7	15.6	0.80	5.9e-03	APEH CADM2 ERCC8 MST1R NEGR1 NRBF2 RBM6 RNF123 UBA7
Arm fat percentage (right)	6.19	13	8	17.8	-0.88	2.8e-05	APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Trunk fat-free mass	2.46	9	7	15.6	-0.40	2.5e-01	CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Hip circumference	4.11	11	8	17.8	-0.68	1.6e-02	APEH CADM2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 THEM6 UBA7
Alcohol intake versus 10 years previously	6.71	6	4	8.9	-0.87	1.0e-02	APEH MST1R NEGR1 RBM6 RNF123 UBA7
Father's age at death	3.39	3	0	0.0	0.00	1.0e+00	APEH RNF123 UBA7
Worrier / anxious feelings	2.29	2	1	2.2	0.00	1.0e+00	AP001877.1 CADM2
Number of live births	2.84	2	0	0.0	0.00	1.0e+00	RBM6 RNF123
Forced expiratory volume in 1-second (FEV1)	1.83	4	0	0.0	0.99	1.4e-02	APEH GPD2 MST1R UBA7
Pulse rate	1.35	1	0	0.0	0.00	1.0e+00	IP6K2
Noisy workplace	3.43	1	0	0.0	0.00	1.0e+00	LIN37
Mouth/teeth dental problems: Dentures	4.43	4	0	0.0	-1.00	2.2e-04	MST1R RBM6 RNF123 UBA7
Prospective memory result	3.28	1	0	0.0	0.00	1.0e+00	RBM6
Forced expiratory volume in 1-second (FEV1), Best measure	2.00	4	0	0.0	1.00	3.3e-03	APEH MST1R RNF123 UBA7
Impedance of arm (left)	4.43	10	7	15.6	0.82	2.0e-03	APEH CADM2 ERCC8 LIN37 MST1R NEGR1 NRBF2 RBM6 RNF123 UBA7
Arm fat mass (right)	7.20	11	8	17.8	-0.88	1.9e-04	APEH CADM2 IP6K2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Trunk predicted mass	2.43	9	6	13.3	-0.39	2.6e-01	CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Standing height	1.20	6	3	6.7	0.97	1.6e-03	CAMKMT FAM160A1 MED8 MPP6 NRBF2 RP11-282O18.3
Exposure to tobacco smoke at home	3.84	2	0	0.0	0.00	1.0e+00	RNF123 UBA7
Breastfed as a baby	2.95	1	0	0.0	0.00	1.0e+00	RP11-282O18.3
Seen doctor (GP) for nerves, anxiety, tension or depression	2.51	1	1	2.2	0.00	1.0e+00	NEGR1
Ever highly irritable/argumentative for 2 days	3.99	4	0	0.0	-1.00	2.2e-04	MST1R RBM6 RNF123 UBA7
Qualifications: O levels/GCSEs or equivalent	9.30	16	3	6.7	0.96	2.2e-09	AP001877.1 APEH ARTN CAMKMT CKM FAM160A1 GPD2 MPP6 MST1R NRBF2 POM121C RNF123 RP11-282O18.3 ST3GAL3 THEM6 TSNARE1
Medication for cholesterol, blood pressure or diabetes	3.56	3	0	0.0	0.00	1.0e+00	RBM6 RNF123 UBA7
Hypothyroidism/myxoedema (self-reported)	1.15	1	0	0.0	0.00	1.0e+00	TANK
Medication: Ventolin 100micrograms inhaler	2.41	2	0	0.0	0.00	1.0e+00	RBM6 UBA7
Chronic bronchitis/emphysema (mother)	3.25	2	0	0.0	0.00	1.0e+00	RBM6 UBA7
Forced vital capacity (FVC), Best measure	1.84	5	0	0.0	0.82	9.0e-02	APEH FOXO6 MST1R RNF123 UBA7
Body fat percentage	6.43	13	10	22.2	-0.89	2.0e-05	APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Leg fat percentage (right)	8.44	14	10	22.2	-0.89	6.8e-06	AP001877.1 APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm fat-free mass (right)	3.82	10	7	15.6	-0.55	7.9e-02	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Exposure to tobacco smoke outside home	3.36	1	0	0.0	0.00	1.0e+00	UBA7
Comparative body size at age 10	2.81	3	2	4.4	0.00	1.0e+00	CADM2 ERCC8 NEGR1
Worry too long after embarrassment	1.64	1	0	0.0	0.00	1.0e+00	THEM6
Wheeze or whistling in the chest in last year	5.25	5	4	8.9	-0.99	1.1e-04	APEH MST1R RBM6 RNF123 UBA7
Number of children fathered	2.36	1	0	0.0	0.00	1.0e+00	CADM2
Age at first live birth	9.04	7	4	8.9	0.99	6.5e-07	AP001877.1 APEH MST1R NRBF2 RBM6 RNF123 UBA7
Health satisfaction	3.01	2	0	0.0	0.00	1.0e+00	TSNARE1 UBA7
Qualifications: College or University degree	18.88	31	20	44.4	0.98	2.1e-24	AP001877.1 APEH ARTN CADM2 CAMKMT CELF2 CKM CUEDC2 ERCC8 FAM160A1 FOXO6 GPD2 GRIN2A IP6K2 LIN37 LONRF2 MAD1L1 MED8 MPP6 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 ST3GAL3 TANK THEM6 TSNARE1 UBA7
Medication for pain relief, constipation, heartburn	2.58	1	0	0.0	0.00	1.0e+00	RP11-282O18.3
Medication: Blood pressure	2.51	1	0	0.0	0.00	1.0e+00	RNF123
Medication: Seretide 50 evohaler	2.85	1	0	0.0	0.00	1.0e+00	UBA7
Mean time to correctly identify matches	2.38	1	0	0.0	0.00	1.0e+00	RNF123
Whole body fat mass	6.91	12	9	20.0	-0.88	6.3e-05	APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Leg fat mass (right)	8.47	12	9	20.0	-0.88	6.3e-05	APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm predicted mass (right)	3.87	10	7	15.6	-0.56	7.0e-02	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Pulse rate, automated reading	3.18	8	5	11.1	-0.85	3.9e-03	APEH IP6K2 MST1R NEGR1 POM121C RBM6 RNF123 UBA7
Alcohol intake frequency.	4.73	8	4	8.9	-0.90	9.7e-04	APEH MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 TSNARE1 UBA7
Comparative height size at age 10	1.72	5	3	6.7	0.99	1.3e-03	CAMKMT FAM160A1 MED8 RP11-282O18.3 ST3GAL3
Overall health rating	7.37	9	6	13.3	-0.99	7.2e-08	APEH CKM MST1R RBM6 RNF123 TANK THEM6 TSNARE1 UBA7
Age at last live birth	8.58	7	4	8.9	0.99	1.1e-06	AP001877.1 APEH LONRF2 MST1R RBM6 RNF123 UBA7
Leg pain on walking	4.72	4	3	6.7	-1.00	4.8e-05	MST1R RBM6 RNF123 UBA7
Qualifications: NVQ or HND or HNC or equivalent	4.30	3	0	0.0	-1.00	2.5e-03	MST1R RBM6 RNF123
Commuting to job workplace: Car/motor vehicle	2.67	1	0	0.0	0.00	1.0e+00	NEGR1
Knee pain experienced in last month	2.83	1	0	0.0	0.00	1.0e+00	RBM6
Hypertension (Self-reported)	1.92	5	0	0.0	-0.64	2.5e-01	MPP6 NEGR1 NRBF2 THEM6 TSNARE1
Smoking status: Previous	2.56	1	1	2.2	0.00	1.0e+00	CADM2
Whole body fat-free mass	2.94	9	8	17.8	-0.46	1.8e-01	CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Leg fat-free mass (right)	2.97	10	8	17.8	-0.49	1.3e-01	CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Arm fat percentage (left)	6.25	13	8	17.8	-0.88	3.3e-05	APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Average weekly red wine intake	5.44	4	1	2.2	0.98	1.8e-02	AP001877.1 CAMKMT NRBF2 RP11-282O18.3
Mood swings	4.47	6	2	4.4	-0.99	4.7e-05	APEH CELF2 MST1R RBM6 RNF123 UBA7
Loneliness, isolation	2.71	1	0	0.0	0.00	1.0e+00	APEH
Long-standing illness, disability or infirmity	2.07	1	0	0.0	0.00	1.0e+00	NEGR1
Ever had bowel cancer screening	2.74	2	0	0.0	0.00	1.0e+00	RNF123 UBA7
Diabetes diagnosed by doctor	3.30	3	1	2.2	-0.99	7.9e-03	RBM6 RNF123 UBA7
Friendships satisfaction	2.13	1	0	0.0	0.00	1.0e+00	AP001877.1
Qualifications: nursing, teaching	9.33	14	6	13.3	0.96	2.6e-08	AP001877.1 APEH CADM2 CELF2 ERCC8 FAM160A1 MAD1L1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 ST3GAL3 UBA7
Mouth/teeth dental problems: Mouth ulcers	1.74	1	0	0.0	0.00	1.0e+00	AP001877.1
Osteoporosis (self-reported)	1.49	1	0	0.0	0.00	1.0e+00	IP6K2
Illnesses of father: None of the above (group 1)	1.53	1	0	0.0	0.00	1.0e+00	CUEDC2
Smoking status: Current	3.26	1	1	2.2	0.00	1.0e+00	ST3GAL3
Whole body water mass	3.02	10	8	17.8	-0.47	1.4e-01	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Leg predicted mass (right)	2.96	10	7	15.6	-0.48	1.3e-01	CADM2 ERCC8 FAM160A1 MST1R NEGR1 POM121C RBM6 RNF123 RP11-282O18.3 UBA7
Arm fat mass (left)	7.12	11	8	17.8	-0.87	2.0e-04	APEH CADM2 IP6K2 LONRF2 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Number of self-reported non-cancer illnesses	2.18	1	1	2.2	0.00	1.0e+00	NEGR1
Miserableness	5.00	7	4	8.9	-0.99	2.9e-06	APEH CELF2 MST1R RBM6 RNF123 TANK UBA7
Financial situation satisfaction	3.81	3	0	0.0	0.00	1.0e+00	APEH RNF123 UBA7
Commuting to job workplace: Public transport	3.77	2	0	0.0	0.00	1.0e+00	LONRF2 NEGR1
High cholesterol (Self-reported)	1.05	1	0	0.0	0.00	1.0e+00	CADM2
Ever smoked	2.59	2	1	2.2	0.00	1.0e+00	CADM2 CELF2
Basal metabolic rate	3.59	10	8	17.8	-0.55	8.1e-02	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Leg fat percentage (left)	8.47	13	11	24.4	-0.90	1.5e-05	APEH CADM2 CAMKMT IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm fat-free mass (left)	4.12	10	7	15.6	-0.58	6.3e-02	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7
Number of operations (self-reported)	2.79	2	0	0.0	0.00	1.0e+00	NEGR1 TANK
Average weekly beer plus cider intake	5.67	6	1	2.2	-0.98	6.4e-05	CADM2 MST1R NRBF2 RBM6 RNF123 UBA7
Irritability	1.21	1	0	0.0	0.00	1.0e+00	CELF2
Risk taking	3.13	3	1	2.2	0.00	1.0e+00	CADM2 FAM160A1 GRIN2A
Fractured/broken bones in last 5 years	1.96	1	0	0.0	0.00	1.0e+00	ERCC8
Age started oral contraceptive pill	3.16	1	0	0.0	0.00	1.0e+00	RNF123
Diastolic blood pressure, automated reading	5.10	12	8	17.8	-0.89	5.7e-05	APEH MED8 MPP6 MST1R NRBF2 POM121C RBM6 RNF123 RP11-282O18.3 THEM6 TSNARE1 UBA7
Unable to work because of sickness or disability	2.24	1	0	0.0	0.00	1.0e+00	ERCC8
Vascular/heart problems diagnosed by doctor	2.21	4	0	0.0	0.40	6.0e-01	MED8 NEGR1 NRBF2 TSNARE1
Pain experienced in last month	3.89	5	0	0.0	1.00	2.2e-06	APEH MST1R RBM6 RNF123 UBA7
Alcohol drinker status: Previous	1.74	1	0	0.0	0.00	1.0e+00	POM121C
Impedance of whole body	3.57	11	9	20.0	0.78	2.7e-03	APEH CADM2 ERCC8 LIN37 MST1R NEGR1 NRBF2 POM121C RBM6 RNF123 UBA7
Leg fat mass (left)	8.56	12	9	20.0	-0.88	6.5e-05	APEH CADM2 IP6K2 LONRF2 MPP6 MST1R NEGR1 POM121C RBM6 RNF123 THEM6 UBA7
Arm predicted mass (left)	4.18	10	7	15.6	-0.58	6.1e-02	APEH CADM2 ERCC8 FAM160A1 MST1R NEGR1 RBM6 RNF123 RP11-282O18.3 UBA7

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	9	0.258	2.3
GTEx	Adipose Visceral Omentum	9	0.442	2.4
GTEx	Adrenal Gland	1	0.069	2.1
GTEx	Artery Aorta	10	0.336	2.3
GTEx	Artery Coronary	2	0.169	2.2
GTEx	Artery Tibial	13	0.346	2.3
GTEx	Brain Caudate basal ganglia	3	0.326	2.4
GTEx	Brain Cerebellar Hemisphere	8	0.537	2.6
GTEx	Brain Cerebellum	7	0.353	2.4
GTEx	Brain Cortex	3	0.290	2.3
GTEx	Brain Frontal Cortex BA9	5	0.541	2.5
GTEx	Brain Hippocampus	1	0.191	2.0
GTEx	Brain Hypothalamus	2	0.339	2.4
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	2.3
GTEx	Brain Putamen basal ganglia	2	0.321	2.4
GTEx	Breast Mammary Tissue	5	0.253	2.4
GTEx	Breast Mammary Tissue (Male)	1	0.084	2.2
GTEx	Breast Mammary Tissue (Female)	5	0.304	2.3
GTEx	Cells EBV-transformed lymphocytes	3	0.211	2.4
GTEx	Cells Transformed fibroblasts	19	0.452	2.3
GTEx	Colon Sigmoid	6	0.410	2.4
GTEx	Colon Transverse	7	0.339	2.4
GTEx	Esophagus Gastroesophageal Junction	6	0.415	2.5
GTEx	Esophagus Mucosa	12	0.361	2.4
GTEx	Esophagus Muscularis	13	0.402	2.4
GTEx	Heart Atrial Appendage	3	0.190	2.5
GTEx	Heart Left Ventricle	5	0.327	2.4
GTEx	Liver	4	0.558	2.3
GTEx	Lung	10	0.348	2.3
GTEx	Muscle Skeletal	10	0.346	2.4
GTEx	Nerve Tibial	19	0.440	2.3
GTEx	Ovary	1	0.110	2.4
GTEx	Pancreas	9	0.551	2.5
GTEx	Pituitary	3	0.269	2.2
GTEx	Prostate	1	0.120	2.3
GTEx	Skin Not Sun Exposed Suprapubic	10	0.407	2.4
GTEx	Skin Sun Exposed Lower leg	14	0.385	2.3
GTEx	Small Intestine Terminal Ileum	3	0.651	2.4
GTEx	Spleen	3	0.213	2.4
GTEx	Stomach	4	0.275	2.4
GTEx	Testis	8	0.254	2.2
GTEx	Thyroid	14	0.350	2.3
GTEx	Uterus	0	0.000	2.4
GTEx	Vagina	1	0.157	2.6
GTEx	Whole Blood	4	0.201	2.2
METSIM	Adipose	11	0.239	2.1
NTR	Blood	9	0.375	2.1
ROSMAP	Brain Pre-frontal Cortex	11	0.251	2.3
YFS	Blood	9	0.195	2.0
CommonMind	Brain Pre-frontal Cortex	10	0.186	2.1
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	4	0.242	2.2
The Cancer Genome Atlas	Breast Invasive Carcinoma	10	0.227	2.1
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	2.2
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	2.1
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	2.0
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.391	2.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	7	0.257	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	11	0.268	2.1
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.439	2.2
The Cancer Genome Atlas	Brain Lower Grade Glioma	13	0.302	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	2.3
The Cancer Genome Atlas	Lung Adenocarcinoma	8	0.272	2.1
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	6	0.239	2.2
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	2.1
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	8	0.482	2.2
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	5	0.377	2.2
The Cancer Genome Atlas	Prostate Adenocarcinoma	11	0.238	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	2.1
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	2.3
The Cancer Genome Atlas	Stomach Adenocarcinoma	3	0.178	2.1
The Cancer Genome Atlas	Testicular Germ Cell Tumors	3	0.235	2.2
The Cancer Genome Atlas	Thyroid Carcinoma	16	0.310	2.0
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	2.1